Adaptive Biotechnologies Corp.
www.adaptivebiotech.com
Latest From Adaptive Biotechnologies Corp.
Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
- Gene Therapy, Cell Therapy
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Pharmaceuticals
- Vaccines
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Services
- Therapeutic Areas
- Cancer
- Immune Disorders
- Infectious & Viral Diseases
- Alias(es)
- Adaptive TCR Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Adaptive Biotechnologies Corp.
- Senior Management
-
Chad Robins, Pres. & CEO
Chad Cohen, CFO
Charles Sang, SVP, Diagnostics
Julie Rubinstein, CBO
Lance Baldo, MD, CMO - Contact Info
-
Adaptive Biotechnologies Corp.
Phone: (855) 466-8667
1551 Eastlake Ave. E
Ste. 200
Seattle, WA 98102
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice